Aquaporin‐4‐IgG‐positive neuromyelitis optica spectrum disorder (AQP4‐IgG+ NMOSD) can cause significant disability after a single attack. Long‐term immunotherapy reduces disability accumulation, but the choice of first‐line therapy varies. In the United… Click to show full abstract
Aquaporin‐4‐IgG‐positive neuromyelitis optica spectrum disorder (AQP4‐IgG+ NMOSD) can cause significant disability after a single attack. Long‐term immunotherapy reduces disability accumulation, but the choice of first‐line therapy varies. In the United Kingdom, rituximab is typically used as escalation therapy after conventional immunosuppressants fail, while in Germany, it is widely used as first‐line treatment.
Keywords:
first line;
positive neuromyelitis;
igg positive;
aquaporin igg;
disability
Journal Title: European Journal of Neurology
Year Published: 2025
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: European Journal of Neurology
Year Published: 2025
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!